Latest Oncology News

FDA Approves Optune Lua for Metastatic NSCLC After Platinum-Based Chemotherapy

October 15th 2024

Chris Ryan

The FDA has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non–small cell lung cancer.

Fox Chase Cancer Center Researchers Propose a New Type of Sarcoma, PHF1::TFE3-Positive Fibromyxoid Sarcoma

October 15th 2024

Fox Chase Cancer Center

A new study from researchers at Fox Chase Cancer Center has found that some ossifying fibromyxoid tumors are malignant sarcomas.

ADCs Usher in a Complex New Era of Disease and Toxicity Management in Bladder Cancer

October 15th 2024

Ashling Wahner

Jacqueline Brown, MD, discusses the nuanced potential role of immunotherapy-ADC and dual-ADC combinations in bladder cancer.

FDA Grants Orphan Drug Designation to IMM-1-104 for Pancreatic Cancer

October 15th 2024

Chris Ryan

The FDA has granted orphan drug designation to IMM-1-104 for pancreatic cancer.

FDA Grants Fast Track Designation to LP-184 for Glioblastoma

October 15th 2024

Ashling Wahner

LP-184 has received fast track designation from the FDA for the treatment of patients with glioblastoma.

Latest Oncology Videos

The Current Treatment Landscape for R/R CLL

Emerging Combinations in Maintenance Therapy for Ovarian Cancer

Dr Sallman on the Significance of the FDA Approval of Luspatercept for Lower-Risk MDS

Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL

Key Takeaways for Concurrent Biomarker Testing in NSCLC

Dr Weinberg on the Prognostic Use of ctDNA Testing in Resected CRC

Dr Ashraf on Ivonescimab vs Pembrolizumab as a First-Line Treatment for PD-L1+ Advanced NSCLC

Dr Tao on the Efficacy of Avelumab/Cetuximab/Radiotherapy in Cisplain-Eligibile vs Ineligible HNSCC

Dr Weiss on Outcomes With Versamune HPV Plus Pembrolizumab in HPV16+ HNSCC

Dr Sonpavde on an Exploratory Analysis of CheckMate 901 in Metastatic Urothelial Cancer

Changing Standard of Care: Potential of Tarlatamab in SCLC Treatment

Dr Voss on the Clinical Significance of the KEYNOTE-564 Study in ccRCC

Genetic Testing – Somatic

ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)

COSMOS-CRC-01: Clinicopathologic Correlation of ctDNA With RFS

Dr Lau on Tarlatamab as Maintenance Therapy in Extensive-Stage SCLC

Defining Platinum Sensitivity in SCLC

Dr Rugo on the FDA Approval of Inavolisib Plus Palbociclib and Fulvestrant in PIK3CA-mutated HR+/HER2– Breast Cancer

Dr Krishnan on the Optimal Use of DKd in Relapsed/Refractory Multiple Myeloma

Dr Amanam on the Evolution of Myelofibrosis Management

Dr Hernandez-Ilizaliturri on Selecting Between CAR T-Cell Therapies for FL

Dr Sridhar on the Use of Zelenectide Pevedotin in Locally Advanced or Metastatic Urothelial Cancer

Dr Wolf on Challenges Conducting Clinical Trials Evaluating Surgery in Mesothelioma

All Oncology News

Toripalimab Wins Approval in India and Hong Kong for Recurrent/Metastatic Nasopharyngeal Carcinoma

October 15th 2024

Chris Ryan

Toripalimab has been approved in India and China’s Hong Kong Special Administrative Region for recurrent or metastatic nasopharyngeal carcinoma.

Lurbinectedin/Atezolizumab Combination Improves Survival in ES-SCLC

October 15th 2024

Ashling Wahner

Lurbinectedin plus atezolizumab produced significant OS and PFS benefits as frontline maintenance for extensive-stage small cell lung cancer.

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

October 15th 2024

Kyle Doherty

Ian Krop, MD, PhD, and Aditya Bardia, MD, MPH, FASCO, detail how TROP2-directed ADCs have generated excitement in breast cancer and other solid tumors.

Increased ctDNA and MMR Testing May Alter Adjuvant and Neoadjuvant CRC Management

October 15th 2024

Ashling Wahner

Benjamin Adam Weinberg, MD, discusses the prognostic value of adjuvant ctDNA testing in CRC and the role of immune checkpoint inhibition in dMMR CRC.

Prospective Trials Could Refine Potential Roles for Radiation in Advanced RCC

October 15th 2024

Ryan Scott

Chad Tang, MD, discusses how radiation could play a role in advanced renal cell carcinoma.

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

October 14th 2024

Aaron Gerds, MD

Drs Gerds and McCloskey discuss JAK inhibitors for patients with myelofibrosis, tips for symptom management, and emerging myelofibrosis research.

NKT2152 Generates Responses in Heavily Pretreated Advanced ccRCC

October 14th 2024

Ashley Chan

NKT2152, a novel HIF2α inhibitor, produced responses in heavily pretreated advanced clear cell renal cell carcinoma.

Selinexor Paves the Way for More Affordable, Effective Treatment Options in Myelofibrosis

October 14th 2024

Courtney Flaherty

Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis.

BTK Inhibitors vs Venetoclax: Considerations for Frontline Treatment Selection in CLL

October 14th 2024

Jax DiEugenio

Nitin Jain, MD, discusses the use of BTK inhibitor– and venetoclax-based regimens for the frontline treatment of chronic lymphocytic leukemia.

Dana-Farber Cancer Institute Delivers ‘Simple Immediate Impact’ to Patient Comfort Using Weighted Blankets

October 14th 2024

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute has used weighted blankets to aid in patient care.

EU Approval Sought for Darolutamide Plus ADT for mHSPC

October 14th 2024

Ryan Scott

The EMA has received a submission seeking the approval of darolutamide in combination with ADT in metastatic hormone-sensitive prostate cancer.

Sunvozertinib Receives Breakthrough Therapy Designation for Treatment-Naive EGFR Exon 20+ NSCLC in China

October 14th 2024

Courtney Flaherty

China’s CDE has granted breakthrough therapy designation to first-line sunvozertinib for EGFR exon 20 insertion mutation–positive NSCLC.

Chemoimmunotherapy Is at the Forefront of the Perioperative NSCLC Paradigm

October 14th 2024

Megan Hollasch

Combination therapies with neoadjuvant ICIs and chemotherapy followed by an adjuvant ICI are here to stay in resectable non–small cell lung cancer.

Empowering Breast Surgeons: A Call for Collective Action

October 14th 2024

David Weintritt, MD, FACS

As survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.

Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma

October 14th 2024

Ryan Scott

CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.

See All News